Therapeutic Effect of Dienogest in Adenomyosis

Dienogest Versus Gonadotropin-Releasing Hormone Agonists or a Low-dose Combined Oral Contraceptive for Treatment of Adenomyosis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900024958

Enrollment

Unknown

Registered

2019-08-05

Start date

2019-09-01

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adenomyosis

Interventions

Group 1:VISANNE 2MG Tablet once daily

Group 2:subcutaneous Goserelin acetate injections (3.6 mg/4 weeks, GoserelinAcetateSustained-ReleaseDepot)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Women aged 18 years or older; 2. Woman complains of menorrhagia or dysmenorrhea; 3. Women with ultrasonographic evidence of adenomyosis.

Exclusion criteria

Exclusion criteria: 1. Woman who is pregnant or nursing; 2. Women who received hormone therapy within 3 months prior to initiation of treatment; 3. Women with uterine fibroids >=2 cm in diameter; 4. Women whose gynecological examination results were abnormal, or cervical cytology smear was abnormal in the past 3 months; 5. Women with abnormal blood coagulation, ovarian tumors, other endocrine diseases.

Design outcomes

Primary

Measure	Time frame
visual analogue scale;Ultrasound;CA125;	—

Countries

China

Contacts

Public ContactWang Guoyun

Qilu Hospital of Shandong University

Wangguoyun@sdu.edu.cn+86 18560081729

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 14, 2026